SEQSTER CEO Ardy Arianpour Named to PharmaVoice 100 for Innovation in Life Sciences

Real World Data Innovator, Arianpour, named for leading industry award for his exemplary leadership and unwavering commitment to putting patients at the center of healthcare

SAN DIEGO–(BUSINESS WIRE)–Seqster PDM, Inc. (“SEQSTER“), the leading healthcare technology company, today announced CEO and Co-Founder Ardy Arianpour has been named to the prestigious 2023 PharmaVoice 100, a recognition of the 100 most inspiring people in the life sciences industry.

Arianpour joins a diverse group of industry leaders who were selected based on their inspirational qualities as well as their ability to innovate, develop breakthrough strategies, and improve the lives of patients. This year’s honorees include: Standout execs, Trailblazers, Cancer care visionaries, Clinical trial gurus, Patient heroes, Entrepreneurs, Tech wizards, Rare disease warriors, and Brand and commercialization pros.

PharmaVoice recognized Arianpour for his visionary leadership, entrepreneurial spirit, and ability to build and execute an innovative patient-centric data technology company that is revolutionizing drug development by connecting patients and their real-time real-world data directly with researchers. Under his leadership, SEQSTER has built an operating system that connects patients, researchers, sponsors and clinical trial sites together to accelerate drug development.

“I am deeply honored to be recognized for the PharmaVoice 100. My mission has always been to place the patient at the center of all their health data, breaking down data silos and transforming clinical research. Our operating system, which includes a digital front door for patients and researchers, has become the preferred technology solution driving real-time Real World Data connectivity, data refinement, and patient engagement for leading life sciences companies such as Boehringer Ingelheim, Takeda, UBC (United BioSource), and national patient registries such as the National Pancreas Foundation (NPF),” stated Ardy Arianpour.

Throughout a distinguished 20-year career in the life sciences sector, Ardy Arianpour has consistently demonstrated a relentless dedication to driving innovation and introducing disruptive products for both patients and researchers. Prior to founding SEQSTER, Arianpour had the privilege of launching various clinical and consumer-based genetic tests while serving as Senior Vice President and General Manager of Genomics at Ambry Genetics, a company that was acquired by Konica for $1 billion in 2017. One of Arianpour’s significant contributions was his pivotal role in the landmark 2013 SCOTUS decision that eliminated gene patents, democratizing access to genetic testing. The introduction of BRCA testing, in particular, had a profound impact on patients, caregivers and their families nationwide.

Arianpour has been widely recognized globally as a pioneer in healthcare with many awards, such as the American Heart Association Health Tech Award 2018, Top 40 Healthcare Transformer by Medical, Marketing, and Media (MM&M 2019), San Diego Business Journal’s 40 Under 40 in 2019, Top Tech Awards in 2021, Top 10 Pioneers Redefining Healthcare in 2021 and Med Tech World Rising Star 2022.

Since 2005, the PharmaVoice 100 has become one of the publication’s most anticipated features. PharmaVoice developed the only awards program in the industry to recognize individuals of all ages representing all sectors of the life sciences industry — from academia to nonprofit organizations to big pharma to emerging biotech companies to technology companies to commercial organizations that provide molecule-to-market services in support of moving the needle to benefit patients around the world. The PharmaVoice 100 continues to contain a diverse mix of people across a range of disciplines — from the clinic to the C-suite — who are making meaningful contributions in their fields of influence.

Arianpour will be presenting how SEQSTER powers pragmatic clinical trials with their newest partner, Optum Life Sciences, at DPHARM Conference – Disruptive Innovations to Modernize Clinical Research, September 21, 2023 at the Westin Copley Conference Center in Boston.

PharmaVoice will recognize this year’s honorees at the 2023 PharmaVoice 100 Exclusive Event: “The NextFrontier of the Life Sciences” on Oct. 25-26. Hosted by award-winning journalists, this event will feature a range of keynotes, panel discussions and fireside chats on the critical trends facing the industry including innovation, genetic medicine, research hot spots, the biotech market, clinical trial tech advancements and more.


SEQSTER is the leading healthcare technology company that breaks down health data silos at scale. Its enterprise operating system aggregates disparate health data sources into a single, 360-degree view of a patient in real-time, solving a multitude of challenges for life sciences, patient engagement and data interoperability.

SEQSTER has nationwide coverage of EHRs from hospitals and medical groups, genomic DNA, wearables, pharmacy and social determinants of health data. Through its customizable white-label approach, SEQSTER provides accelerated access to de-identified, tokenized, real-time data and comprehensive curated data to address critical needs across the healthcare continuum.

SEQSTER is privately held and headquartered in San Diego.

To learn more about the Seqster Operating System for Clinical Studies, Patient Registries and the Digital Front Door, please contact us at [email protected] or visit

About PharmaVoice

PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.

About Industry Dive

Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.


Bill Douglass


[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.